Search results for " pharmacokinetics"

showing 10 items of 24 documents

A Pharmacological Update of Ellagic Acid.

2018

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0633-9492.pdf This is a pre-print of an article published in Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093. The final authenticated version is available online at: https://doi.org/10.1055/a-0633-9492 Este es el pre-print del siguiente artículo Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093 que se ha publicado de forma definitiva en https://doi.org/10…

0301 basic medicineEllagic acid - Pharmacokinetics.Antioxidantmedicine.medical_treatmentMetaboliteInterleukin-1betaAnti-Inflammatory AgentsPharmaceutical ScienceApoptosisPharmacologyProtective AgentsProteína quinasa.NeuroprotectionAntioxidantsAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEllagic AcidGlycationDrug DiscoverymedicineHumansProtein kinases.Cell ProliferationPharmacologyMetabolic SyndromeAldose reductaseInterleukin-6Tumor Necrosis Factor-alphaMetabolismo - Trastornos.Organic ChemistryNF-kappa BLipid metabolismAtherosclerosisEllagic acid - Physiological effect.NeuroprotectionMetabolism disorder030104 developmental biologyComplementary and alternative medicinechemistryÁcido elágico - Efectos fisiológicos.Antioxidantes.Ácido elágico - Farmacocinética.030220 oncology & carcinogenesisMolecular MedicineMetabolism - Disorders.Antioxidants.Ellagic acidPlanta medica
researchProduct

Chiral Serum Pharmacokinetics of 4-Fluoroamphetamine after Controlled Oral Administration

2021

Abstract Over the last two decades, misuse of 4-fluoroamphetamine (4-FA) became an emerging issue in many European countries. Stimulating effects last for 4–6 hours and can impact psychomotor performance. The metabolism of amphetamine-type stimulants is stereoselective and quantification of (R)- and (S)-enantiomers has been suggested for assessing time of use. To date, no data on enantioselective pharmacokinetics is available for 4-FA in serum samples. An enantioselective liquid chromatography−tandem mass spectrometry (LC–MS-MS) method was developed using a chiral Phenomenex® Lux 3 μm AMP column. Validation of the method showed satisfactory selectivity, sensitivity, linearity (0.5–250 ng/mL…

3SAMPLESHealth Toxicology and MutagenesisNETHERLANDSAdministration OralAMPHETAMINEMETABOLISMMETHAMPHETAMINEToxicology01 natural sciencesSTEREOSELECTIVE PHARMACOKINETICSAnalytical Chemistry03 medical and health sciences4-Fluoroamphetamine0302 clinical medicinePharmacokineticsTandem Mass SpectrometryOral administrationmedicineHumansEnvironmental ChemistryIngestion030216 legal & forensic medicineChemical Health and SafetyChromatography34-METHYLENEDIOXYMETHAMPHETAMINEChemistryAmphetamines010401 analytical chemistryTRANSPORTERStereoisomerism4-METHYLENEDIOXYMETHAMPHETAMINESerum samples0104 chemical sciencesStereoselectivityFLUOROAMPHETAMINEEnantiomerPSYCHOACTIVE SUBSTANCES NPSTime of useChromatography Liquidmedicine.drugJournal of Analytical Toxicology
researchProduct

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.

2012

Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naïve patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800–1400 mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44.2% of Peg-…

AdultMaleAdolescentInterferon alpha-2Antiviral AgentsPolyethylene GlycolsYoung AdultSex FactorsRibaviringenderHumansAgedSettore MED/12 - GastroenterologiaPeg IFNAge FactorsInterferon-alphaHepatitis C ChronicMiddle Agedcentral fat distribution cytokines metabolic syndrome pharmacokinetics sustained virological responseRecombinant ProteinsTreatment OutcomeDrug Therapy CombinationFemaleEpatite HCV; Peg IFN; genderMenopauseSettore SECS-S/01 - StatisticaEpatite HCVJournal of viral hepatitis
researchProduct

Nonlinear pharmacokinetics of fluvoxamine and gender differences.

1998

This prospective study assessed fluvoxamine serum concentrations under two different fixed doses. The study included 15 male and female patients who met the DSM-III-R criteria for major depression. They were prescribed 50 mg fluvoxamine twice a day for 2 weeks and 100 mg twice a day thereafter. Drug monitoring was carried out on days 14 and 28. Fluvoxamine serum concentrations were highly variable between patients. After the dose was doubled, the serum concentrations of fluvoxamine increased disproportionately (mean, 3.4-fold), and there was a significantly (p < 0.05) more pronounced increase in men (4.6-fold) than in women (2.4-fold). These results provide evidence of nonlinear, sex-depend…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentFluvoxamineGastroenterologySex FactorsPharmacokineticsOral administrationInternal medicinemedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyAgedPharmacologyAged 80 and overChemotherapyDepressive DisorderDose-Response Relationship Drugbusiness.industryNonlinear pharmacokineticsMiddle AgedDose–response relationshipFluvoxamineAnesthesiaAntidepressive Agents Second-GenerationFemalebusinessReuptake inhibitormedicine.drugTherapeutic drug monitoring
researchProduct

Rilevanza clinica delle interazioni farmacologiche di tipo farmacocinetico [Clinical significance of pharmacokinetic interactions]

2008

The correct realization of a pharmacological therapy needs the individuation of the most appropriate drugs for the treatment of the patient's disease. However, even the most effective, and potent and appropriate drugs cannot assure the therapeutic success, if that compound does not reach the site of action. This result can be obtained only if the physician knows the factors that regulate thepharmacokinetic parameters of the used drugs, i.e. absorption, distribution, metabolism, excretion, that regulate the onset velocity, the duration and the intensity of the drug effects. In the lost years, pharmacological interactions, i.e. the possibility that co-administered drugs interfere with each ot…

Clinical significance Pharmacokinetics Pharmacological interactionsSettore BIO/14 - Farmacologia
researchProduct

Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.

2016

Second-generation antipsychotics (SGAs) are frequently co-prescribed with drug metabolic inducers and inhibitors. SGA pharmacokinetic drug-drug interactions (DDIs) with inducers and inhibitors have not received enough attention in the literature but can be studied in by using therapeutic drug monitoring (TDM).The limited information available on oral SGA pharmacokinetic DDIs is reviewed. A systematic literature search on the available oral SGA TDM studies is completed. By integrating TDM studies with the information on in vitro metabolism studies, case report/series and prospective studies, a table is provided to manage average SGA patients taking inducers or inhibitors by using TDM and/or …

DrugDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjecttherapeutic drug monitoringAdministration OralPharmacologyToxicology030226 pharmacology & pharmacyDrug interactions03 medical and health sciences0302 clinical medicinePharmacokineticsinhibitorsMedicineHumansProspective cohort studyClozapinemedia_commonLurasidoneinducersPharmacologyRisperidonemedicine.diagnostic_testDose-Response Relationship Drugbusiness.industrysecond-generation antipsychoticsGeneral MedicineDrug interactions; inducers; inhibitors; pharmacokinetics; second-generation antipsychotics; therapeutic drug monitoring030227 psychiatryTherapeutic drug monitoringQuetiapineAntidepressive Agents Second-GenerationDrug Monitoringbusinesspharmacokineticsmedicine.drugAntipsychotic Agents
researchProduct

Influence of Chemical Enhancers and Iontophoresis on the In Vitro Transdermal Permeation of Propranolol: Evaluation by Dermatopharmacokinetics

2018

[EN] The aims of this study were to assess, in vitro, the possibility of administering propranolol transdermally and to evaluate the usefulness of the dermatopharmacokinetic (DPK) method in assessing the transport of drugs through stratum corneum, using propranolol as a model compound. Four chemical enhancers (decenoic and oleic acid, laurocapram, and R-(+)-limonene) and iontophoresis at two current densities, 0.25 and 0.5 mA/cm(2) were tested. R-(+)-limonene, and iontophoresis at 0.5 mA/cm(2) were proven to be the most efficient in increasing propranolol transdermal flux, both doubled the original propranolol transdermal flux. Iontophoresis was demonstrated to be superior than the chemical…

Drugdermatopharmacokineticsmedia_common.quotation_subjectChemical enhancerslcsh:RS1-441Pharmaceutical SciencePropanol - Uso terapéutico.02 engineering and technologyPropranololMedicamentos - Administración.030226 pharmacology & pharmacyArticlelcsh:Pharmacy and materia medicaIonización.03 medical and health sciences0302 clinical medicineIonization.medicineStratum corneumpropranololDermatopharmacokineticsTransdermalmedia_commonchemical enhancersChromatographytransdermal administrationIontophoresisChemistryLaurocapramTransdermal administrationIontophoresisDrugs - Administration.Skin absorption.iontophoresisPermeation021001 nanoscience & nanotechnologyPropranololPropanol - Therapeutic use.In vitromedicine.anatomical_structurePropanol - Pharmacokinetics.Propanol - Farmacocinética.Absorción cutánea.0210 nano-technologymedicine.drugPharmaceutics
researchProduct

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolong…

2014

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect -

HeredityPharmacokinetic inherited Factor VII deficiencyFactor VII DeficiencySocio-culturaleFactor VIIaPharmacologySeverity of Illness IndexPharmacokineticsPredictive Value of Testshemic and lymphatic diseasesHumansMedicineGenetic Predisposition to DiseaseFVII deficiencyRegistriescardiovascular diseasesBlood CoagulationVolume of distributionbiologyCoagulantsbusiness.industryVascular biologyrFVIIaHematologyFactor VIIRecombinant ProteinsPhenotypeTreatment OutcomerFVIIa; FVII deficiency; pharmacokineticsRecombinant factor VIIaPharmacodynamicsbiology.proteinBlood Coagulation TestsSteady state (chemistry)Drug Monitoringbusinesspharmacokinetics
researchProduct

DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?

2014

Background. Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether α-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome.Methods. This was a prospective, multinational pharmacokinetic point-prevalence study including 8 α-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f TMIC) an…

MaleInternational CooperationAntibioticsadverse eventintensive care unitlaw.invention0302 clinical medicinemeropenemModels[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesadverse events; continuous infusion; extended infusion; pharmacodynamics; pharmacokinetics; Aged; Anti-Bacterial Agents; Bacterial Infections; Blood Chemical Analysis; Female; Humans; Intensive Care Units; International Cooperation; Male; Microbial Sensitivity Tests; Middle Aged; Models Statistical; Prospective Studies; Treatment Outcome; beta-Lactams; Critical Illnessantibiotic therapyProspective Studiesamoxicillin plus clavulanic acidComputingMilieux_MISCELLANEOUSbeta lactam antibioticAPACHE0303 health sciencescritical illneadultclinical trial3. Good healthcontinuous infusion; extended infusion; adverse events; pharmacokinetics; pharmacodynamics.antiinfective agent[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitologypriority journaldisease severitybeta-Lactamstatistical model Agedprospective studyHumanMicrobiology (medical)medicine.medical_specialtydrug exposureCritical IllnessImmunologybloodstream infectionMicrobial Sensitivity Testspiperacillin plus tazobactambeta-LactamsMicrobiologybeta lactam abdominal infection03 medical and health sciencescritically ill patientIntensive careAnti-Bacterial AgentcefepimepharmacodynamicsHumansDosingAdverse effectAgedModels Statistical030306 microbiologyOdds ratiomajor clinical studymortalityantibiotic sensitivityceftriaxoneProspective Studiemulticenter studypharmacodynamics.ampicillinBlood Chemical AnalysisCeftazidimeSettore MED/41 - AnestesiologiaInterquartile rangelaw030212 general & internal medicinepharmacokineticlung infectionMicrobial Sensitivity TestarticleBacterial InfectionsMiddle AgedStatisticalcontinuous infusionIntensive care unitAnti-Bacterial Agentsextended infusionIntensive Care UnitsInfectious DiseasesTreatment Outcomeadverse events; continuous infusion; extended infusion; pharmacodynamics; pharmacokinetics; Aged; Anti-Bacterial Agents; Bacterial Infections; Blood Chemical Analysis; Female; Humans; Intensive Care Units; International Cooperation; Male; Microbial Sensitivity Tests; Middle Aged; Models Statistical; Prospective Studies; Treatment Outcome; beta-Lactams; Critical Illness; Microbiology (medical); Infectious Diseasescefazolin[SDV.IMM]Life Sciences [q-bio]/Immunologyblood samplingFemalepharmacokineticsmedicine.drugmedicine.drug_classprevalencedoripenemminimum inhibitory concentrationBacterial InfectionInternal medicinemedicinecontrolled studyblood analysibusiness.industryBlood Chemical Analysiadverse eventsSurgerypharmacodynamicdrug blood levelbusiness
researchProduct

Rats with congenital hydronephrosis show increased susceptibility to renal ischemia‐reperfusion injury

2020

Abstract Many drug candidates have shown significant renoprotective effects in preclinical models; however, there is no clinically used effective pharmacotherapy for acute kidney injury. The failure to translate from bench to bedside could be due to misleading results from experimental animals with undetected congenital kidney defects. This study was performed to assess the effects of congenital hydronephrosis on the functional capacity of tubular renal transporters as well as kidney sensitivity to ischemia‐reperfusion (I‐R)‐induced injury in male Wistar rats. Ultrasonography was used to distinguish healthy control rats from rats with hydronephrosis. L‐carnitine or furosemide was administer…

Malemedicine.medical_specialtyPhysiologyhydronephrosis pharmacokinetics renal ischemia-reperfusion ultrasonographyUrologyUrine030204 cardiovascular system & hematologyKidneylcsh:Physiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacotherapyhydronephrosisPharmacokineticsFurosemideCarnitinePhysiology (medical)medicineAnimalsRats WistarDiureticsHydronephrosisCreatinineKidneylcsh:QP1-981business.industryAcute kidney injuryFurosemideOriginal ArticlesultrasonographyAcute Kidney Injurymedicine.diseaseRatsrenal ischemia‐reperfusionmedicine.anatomical_structurechemistryReperfusion InjuryOriginal ArticleDisease SusceptibilitybusinessCell Adhesion Moleculespharmacokinetics030217 neurology & neurosurgerymedicine.drugPhysiological Reports
researchProduct